Skip to content

Scot Hasselman

Co-chair Reed Smith LLP

Scot is co-chair of Reed Smith’s global Life Sciences Health Industry Group. He serves as a trusted advisor, effective advocate, and creative but practical problem solver for clients across the health care industry. With decades of experience counseling health care companies and investors, Scot provides knowledgeable and pragmatic advice in high-stakes government investigations and litigation, fast-paced health care transactions, and the development of cutting-edge business arrangements. During the COVID-19 public health emergency, Scot used his dexterity and deep industry experience to provide effective support and counseling to a number of clients in an evolving and uncertain regulatory landscape. Scot’s client base is broad and includes some of the largest health care companies in the United States. His clients include post-acute providers, institutional and retail pharmacies, manufacturers, managed care organizations, digital health companies, providers of outpatient rehabilitation, optometry and dental services, and investors, including private equity firms. Scot’s practice focuses on health care regulatory and policy matters. He has considerable experience with False Claims Act defense, internal and government investigations, compliance with the federal anti-kickback statute (AKS) and physician self-referral (Stark) law and corollary state laws. Notably, Scot has negotiated numerous government settlements and corporate integrity agreements, including some of the most significant settlements of the past several decades. He also advises health care providers, life sciences clients, private equity and other industry investors on regulatory due diligence in various health care transactions, including mergers and acquisitions. Additionally, Scot has a deep interest in health policy and industry trends and clients and others frequently turn to him to consider the evolution of the health care industry, ever-changing laws and regulations, and the potential impact on health care and life sciences companies.